Could common diabetes pills help Parkinson's and dementia?

NCT ID NCT06263673

Completed Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study tested whether two diabetes medications, sitagliptin and dapagliflozin, are safe and can improve movement and thinking in people with Parkinson's disease or Lewy body dementia. 18 participants took either a drug or a placebo daily for a short time. The goal was to see if these drugs could help control symptoms, not cure the diseases.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sitagliptin and dapagliflozin (diabetes medications)
What this could lead to: If successful, these common diabetes drugs could offer a new, well-tolerated option to help manage symptoms of Parkinson's disease and Lewy body dementia.
What could go wrong: This is a very small, early-phase trial with only 18 participants, so results may not apply to everyone. The drugs are not expected to cure these conditions, only possibly ease symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEWY BODY DEMENTIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Lewy body dementia Lewy Body Disease Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEWY BODY DEMENTIA PARKINSON DISEASE

Contacts and locations

Locations

Mayo Clinic Florida

Jacksonville, Florida, 32224, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.